Drugs that contain Dexmedetomidine Hydrochloride
1. List of Dexmedetomidine Hydrochloride drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9649296 | HQ SPCLT PHARMA | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container |
Apr, 2036
(13 years from now) | |
| US9717796 | HQ SPCLT PHARMA | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container |
Apr, 2036
(13 years from now) | |
Market Authorisation Date: 21 October, 2015
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
2. List of Igalmi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10792246 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(16 years from now) | |
| US11497711 | BIOXCEL | NA |
Jun, 2039
(16 years from now) | |
| US11478422 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(16 years from now) | |
| US11517524 | BIOXCEL | NA |
Jun, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Apr 5, 2025 |
Market Authorisation Date: 05 April, 2022
Treatment: Acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by sublingual administration
Dosage: FILM;BUCCAL, SUBLINGUAL
3. List of Precedex drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8455527 | HOSPIRA | Methods of treatment using a dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
| US8648106 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
| US9616049 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
| US8242158 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
| US10016396 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
| US9320712 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
| US8338470 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
|
US8648106
(Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
|
US8242158
(Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
|
US8455527
(Pediatric) | HOSPIRA | Methods of treatment using a dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
|
US8338470
(Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
|
US9320712
(Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
|
US9616049
(Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
Market Authorisation Date: 17 December, 1999
Treatment: Use for sedation
Dosage: INJECTABLE;INJECTION
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic